Pancreatic Cancer Research

ResearcherKumamoto UniversityNo recent work listed

Hideo Baba

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109324170. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 3 papers

Papers 11

  1. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Co-author DOI 10.1245/s10434-022-12566-1↗
  2. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. Co-author DOI 10.1245/s10434-023-13534-z↗
  3. Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers15020498↗
  4. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
  5. Survival Impact of Perioperative Red Blood Cell Transfusion During Pancreatectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Propensity Score Matchin… Last author DOI 10.1097/mpa.0000000000001997↗
  6. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33284↗
  7. Frailty is associated with poor prognosis after resection for pancreatic cancer. Last author DOI 10.1007/s10147-021-01983-z↗
  8. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.15071↗
  9. ASO Author Reflections: Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single Institutio… Last author DOI 10.1245/s10434-020-09039-8↗
  10. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  11. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer. Last author DOI 10.1245/s10434-017-5799-1↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 5 shared papers, 2020–2023 · strength 0.79
  2. Norio Uemura · 3 shared papers, 2021–2023 · strength 0.45
  3. Katsunori Imai · 3 shared papers, 2021–2022 · strength 0.39
  4. Yuki Kitano · 2 shared papers, 2022–2023 · strength 0.32
  5. Tatsunori Miyata · 2 shared papers, 2020–2021 · strength 0.32
  6. Akira Chikamoto · 3 shared papers, 2017–2022 · strength 0.28
  7. Takashi Matsumoto · 2 shared papers, 2021–2022 · strength 0.26
  8. Takayoshi Kaida · 2 shared papers, 2021–2022 · strength 0.26
  9. Rumi Itoyama · 2 shared papers, 2021–2022 · strength 0.26
  10. Fumimasa Kitamura · 2 shared papers, 2021 · strength 0.24
  11. Masayuki Sho · 2 shared papers, 2021–2022 · strength 0.23
  12. Kazuyoshi Nishihara · 2 shared papers, 2019–2023 · strength 0.22
  13. Hiroshi Kurahara · 2 shared papers, 2019–2023 · strength 0.22
  14. Susumu Eguchi · 2 shared papers, 2019–2023 · strength 0.22
  15. Masafumi Inomata · 2 shared papers, 2019–2023 · strength 0.22
  16. Hirokazu Noshirο · 2 shared papers, 2019–2023 · strength 0.22
  17. Yoshihiro Miyasaka · 2 shared papers, 2019–2023 · strength 0.22
  18. Takao Ohtsuka · 2 shared papers, 2019–2023 · strength 0.22
  19. Hiroki Sato · 1 shared paper, 2023 · strength 0.20
  20. Zhao Liu · 1 shared paper, 2023 · strength 0.20
  21. Yosuke Inoue · 1 shared paper, 2023 · strength 0.17
  22. Takashi Sasaki · 1 shared paper, 2023 · strength 0.17
  23. Tsuyoshi Takeda · 1 shared paper, 2023 · strength 0.17
  24. Yoshihiro Ono · 1 shared paper, 2023 · strength 0.17
  25. Masato Ozaka · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.